TheraPPI Bioscience

OUR APPROACH

We modify protein interactions to offer treatments where current therapies fail. Our approach represents a paradigm shift in tackling cancer resistance and non-curable rare diseases

OUR MISSION

We are building a portfolio of small molecules modifying protein interactions against resistant cancers and rare diseases.

THE ISSUE

The prognosis of patients with advanced cancers remains poor. The RAS-MAPK signaling is hyperactivated in over 40% of human cancers and RAS-MAPK-activating mutations cause rare diseases. The efficacy of current RAS-MAPK inhibitors is undercut by cancer resistance and by their inability to cure these rare diseases.

OUR OFFER

TheraPPI’s two first programs target a novel protein interaction in the RAS-MAPK pathway discovered by the founder team. Our first program in oncology revolutionizes RAS-MAPK targeting: the new mode of action leverages a dual mechanism with killing cancer cells and activating an anti-tumoral immune response.

Our lead program aims to obtain a high rate of clinical responses, to circumvent cancer resistance and to improve the response of immunotherapies and thus to offer a better prognosis to patients with advanced cancer.

ABOUT US

The management team has proven expertise in key areas for a biotech company encompassing identification of novel drug targets, discovery and development of small molecule modifying protein interactions, executive experience in pharma-biotech, and financing.